{"id":"W2953546931","doi":"10.1093/annonc/mdz155.224","title":"Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"ca_institutions":"Alberta Health Services","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Clinical endpoint; Oncology; Phases of clinical research; Progression-free survival; Chemotherapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002405342,0.002946642,0.00505122,0.0004068695,0.0005945066,0.001836322,0.001476514,0.00203318,0.006203012],"category_scores_gemma":[0.002743578,0.001105313,0.003983863,0.0005362201,0.001664657,0.002277789,0.0006630279,0.006424611,0.001336615],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001563233,"about_ca_system_score_gemma":0.002045848,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001619204,"about_ca_topic_score_gemma":0.003914039,"domain_scores_codex":[0.9992574,0.0004165808,0.00003289583,0.0001373305,0.00004394018,0.0001119017],"domain_scores_gemma":[0.9987557,0.0003293042,0.0002946933,0.0001327405,0.00008255539,0.000405117],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9797828,0.00436807,0.0005458033,0.0004684,0.001613585,0.00004256839,0.00006223341,0.0006446433,0.001575988,0.0001706024,0.001405087,0.009320233],"study_design_scores_gemma":[0.9691252,0.02850338,0.0007362614,0.00001670302,0.0004408419,0.00003771163,0.0000231484,0.0003065488,0.0001739735,0.0001668348,0.0004525736,0.00001680057],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9810737,0.006159679,0.001220715,0.002059496,0.00115261,0.003933703,0.002178273,0.0002096757,0.002012172],"genre_scores_gemma":[0.9774476,0.003999324,0.003523574,0.002523545,0.0006251188,0.004663623,0.003038062,0.00009331121,0.004085787],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006203012,"threshold_uncertainty_score":0.02075118,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1114819937646863,"score_gpt":0.405950691722312,"score_spread":0.2944686979576256,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}